Rapalogs reduce tumor size by inhibiting the dysregulated activity of mTORC1 that results from biallelic inactivation of TSC1 or TSC2 and loss of activity of the encoded proteins, namely TSC1 (hamartin) or TSC2 (tuberin), which act as repressors of the metabolic activator kinase mTOR7. This evidence concerns the gene TSC2 and neoplasm.